ArticlePloS one2014
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.Journal of translational medicine · 2025Article
- Preclinical Characterization of theInternational journal of molecular sciences · 2023Article
- Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy.Frontiers in pharmacology · 2023Article
- Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).International journal of molecular sciences · 2022Article
- Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.Cancers · 2022Article
- And Yet It Moves: Oxidation of the Nuclear Autoantigen La/SS-B Is the Driving Force for Nucleo-Cytoplasmic Shuttling.International journal of molecular sciences · 2021Article
- Two Be or Not Two Be: The Nuclear Autoantigen La/SS-B Is Able to Form Dimers and Oligomers in a Redox Dependent Manner.International journal of molecular sciences · 2021Article
- T Cell Mediated Conversion of a Non-Anti-La Reactive B Cell to an Autoreactive Anti-La B Cell by Somatic Hypermutation.International journal of molecular sciences · 2021Article
- Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.Oncoimmunology · 2020Article
- Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.Molecular therapy oncolytics · 2020Article
- Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.Journal of experimental & clinical cancer research : CR · 2020Article
- "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.Scientific reports · 2020Article
- UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.Oncoimmunology · 2020Article
- Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.Cancer immunology, immunotherapy : CII · 2019Article
- Engineering switchable and programmable universal CARs for CAR T therapy.Journal of hematology & oncology · 2019Review
- A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.Scientific reports · 2018Article
- From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cellsOncotarget · 2018Article
- Retargeting of UniCAR T cells with anOncotarget · 2018Article
- Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Oncotarget · 2017Article
- Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically engineered T lymphocytes are a promising option for cancer therapy. Prior to adoptive transfer they have to be expanded in vitro to reach therapeutically sufficient numbers. So far, no universal method exists for selective in vitro expansion of engineered T lymphocytes. In order to overcome this problem and for proof of concept we incorporated a novel unique peptide sequence of ten amino acids as epitope (E-Tag) into the binding domains of two novel chimeric antigen receptors (ECARs) directed against either prostate stem cell antigen (PSCA) for the treatment of prostate cancer (PCa) or CD33 for the treatment of acute myeloide leukemia (AML). The epitope tag then was utilized for expanding ECAR engrafted T cells by triggering the modified T cells via a monoclonal antibody directed against the E-Tag (Emab). Moreover, the E-Tag served as an efficient selection epitope for immunomagnetic isolation of modified T cells to high purity. ECAR engrafted T cells were fully functional and mediated profound anti-tumor effects in the respective models of PCa or AML both in vitro and in vivo. The method can be integrated straightforward into clinical protocols to improve therapeutic efficiency of tumor treatment with CAR modified T lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.